Liver Transplantation and Uveal Malignant Melanoma

Uveal Malignant Melanoma Clinical Trial

Official title:

Open Non-randomized Study to Assess the Benefit of Liver Transplantation in Patients With Liver Metastasis After Ocular Malignant Melanoma (Uveal Melanoma)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01311466
• Other study ID #: S-06408
• Status: Completed
• Phase: N/A
• First received: March 7, 2011
• Last updated: October 20, 2017
• Start date: January 2011
• Est. completion date: October 2015

Study information

• Verified date: October 2017
• Source: Oslo University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with uveal malignant melanoma with liver metastases have median survival of less than 12 months. There is no established treatment showing increased overall survival. The study will determine if liver transplantation will result in long term survival in patients with liver metastases from uveal malignant melanoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2
• Est. completion date: October 2015
• Est. primary completion date: October 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Uveal malignant melanoma

• Liver metastases

• ECOG 0-1

Exclusion Criteria:

• Extra hepatic disease

• Previous other malignancy

• Previous organ transplantation

Related Conditions & MeSH terms

• Melanoma
• Uveal Malignant Melanoma

Intervention

Procedure:
• Liver transplantation

Locations

Country	Name	City	State
Norway	Oslo University Hospital	Oslo

Sponsors (1)

Lead Sponsor	Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Over all survival	Patient survival after livertransplantation	1 year